greg_weaver

Oryzon Genomics names CFO and executive VP

pharmafile | January 13, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gregory Weaver, Oryzon genomics 

Spanish clinical stage biopharma firm Oryzon Genomics has appointed Gregory Weaver as its executive vice president and chief financial officer.

Weaver brings more than 30 years of experience to Oryzon, including extensive financial and operational experience with several biotechnology companies. 

Weaver will report directly to Carlos Buesa, the firm’s president and chief executive, and will be based at Oryzon’s US headquarters in Cambridge, MA.

Advertisement

Weaver has served as CFO of several public biotech companies in the US, most recently at Fibrocell Science. Previous to Fibrocell he was CFO at Celsion, Poniard Pharmaceuticals and Sirna Therapeutics.

He also currently serves as non-executive director of Egalet Corporation and Atossa Genetics.

Buesa says: “I am very pleased to welcome Greg to the Oryzon management team. I had the pleasure of working with Greg as a director of Oryzon and have highly valued his contribution to the company thus far.  

“He is a highly experienced international CFO and his significant experience with US listed biotech companies will be very valuable to our executive team as we drive our strategic and financial business forward with particular focus on the US.”

Related Content

Oryzon Genomics announces publication of phase 2a ALICE trial results

Oryzon Genomics has announced that the final results from its phase 2a ALICE study have …

The Gateway to Local Adoption Series

Latest content